SCHEMBL10034796

SCHEMBL10034796

C=C(C)c1ccc2cc1OCCOCCOCCOCCOCCOc1cc-2ccc1C(=C)O[Si](C)(C)C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.35
▸ RECQL P46063 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ ALOX5 P09917 1/20 0.34
▸ CSNK2A1 P68400 5/20 0.34
▸ MAPT P10636 4/20 0.33
▸ LMNA P02545 4/20 0.33
▸ SMN1; SMN2 Q16637 3/20 0.33
▸ HTT P42858 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CSNK2A2 P19784 2/20 0.32
▸ CYP11B1 P15538 1/20 0.31
▸ CYP11B2 P19099 1/20 0.31
▸ CRHBP P24387 2/20 0.31
▸ CRHR2 Q13324 2/20 0.31
▸ GAK O14976 1/20 0.31
▸ STK17B O94768 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067201 0.95 ALOX5 (0.37) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL10034797 0.85 KDM4E (0.38) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL881633 0.82 KDM4E (0.36) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL10034802 0.72 KDM4E (0.54) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL10034793 0.71 KDM4E (0.43) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL881347 0.70 KDM4E (0.44) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL881598 0.63 KDM4E (0.40) BLML3MBTL1KDM4EALOX5CSNK2A1
SCHEMBL5058377 0.62 PRKDC (0.45) POLBKDM4EMAPTLMNAHTT
SCHEMBL881625 0.60 KDM4E (0.61) POLBRECQLBLML3MBTL1KDM4E
SCHEMBL6299023 0.58 KMT2A (0.44) POLBRECQLL3MBTL1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822520-B2 Substituted bicyclic HCV inhibitors PRESIDIO PHARMACEUTICALS, INC. (US) 2014-09-02 — — US disclosed
US-20130178507-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2013-07-11 — — US disclosed
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-02-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178507-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS HAVCR2, LIPC, EIF2AK2 POLB 930/4885RECQL 2051/4885BLM 1089/4885
US-20120028978-A1 SUBSTITUTED BICYCLIC HCV INHIBITORS HAVCR2, LIPC, EIF2AK2 POLB 930/4885RECQL 2051/4885BLM 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback